CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionGross margin is 99.5%, higher than 95% of its Biotechnology peers (median 78%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
1.06BUSDvs all stocks (USD)
Revenue (TTM)
69.64MUSDvs all stocks (USD)
Profit Margin
-37.46%vs Biotechnology peers
Beta
1.05xvs all stocks
52-Week Change
94.31%vs all stocks
Market Capitalization
1.06BUSDvs all stocks (USD)
Enterprise Value
948.68MUSDvs all stocks (USD)
Forward P/E
-11.59xvs Biotechnology peers
Price to Sales (TTM)
15.24xvs Biotechnology peers
Price to Book (MRQ)
4.99xvs Biotechnology peers
Enterprise to Revenue
13.62xvs Biotechnology peers
Enterprise to EBITDA
-40.07xvs Biotechnology peers
Gross Margin
99.49%vs Biotechnology peers
Profit Margin
-37.46%vs Biotechnology peers
Operating Margin
-4.72%vs Biotechnology peers
Return on Assets (TTM)
-5.35%vs Biotechnology peers
Return on Equity (TTM)
-16.01%vs Biotechnology peers
Revenue (TTM)
69.64MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1870USDUpdated Jul 19, 2026Quarterly Revenue Growth
1572.10%vs Biotechnology peers
Gross Profit (TTM)
65.55MUSDvs all stocks (USD)
EBITDA (TTM)
-23.67MUSDvs all stocks (USD)
Net Income (TTM)
-26.09MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1572.11%vs Biotechnology peers
Operating Cash Flow (TTM)
-38.80MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-28.86MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
49.80MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
274.00KUSDFY2025 · Dec 31, 2025Gross Profit
49.53MUSDFY2025 · Dec 31, 2025Operating Income
-48.91MUSDvs all stocks (USD)
Pre-tax Income
-50.34MUSDFY2025 · Dec 31, 2025Net Income
-50.34MUSDFY2025 · Dec 31, 2025EBIT
-42.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-41.38MUSDFY2025 · Dec 31, 2025Research & Development
61.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
37.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-50.34MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-65.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-65.67MUSDDerived from operating cash flow minus capital expenditure. This filing charges 621K of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -67.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
63.33MUSDFY2025 · Dec 31, 2025Interest Paid
8.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-50.34MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
621.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-42.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-30.22MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
707.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-139.84MUSDFY2025 · Dec 31, 2025Sale of Investments
252.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
113.02MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-48.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-572.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-48.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
423.77MSharesUpdated Jul 19, 2026Float Shares
262.53MSharesUpdated Jul 19, 2026Shares Short
30.78MSharesUpdated Jul 19, 2026Short Ratio
7.02daysvs all stocks
Short % of Shares Outstanding
13.08%vs all stocks
% Held by Insiders
1.12%vs all stocks
% Held by Institutions
78.52%vs all stocks
Total Cash (MRQ)
170.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3840USDUpdated Jul 19, 2026Total Debt (MRQ)
57.71MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2845xvs Biotechnology peers
Current Ratio (MRQ)
18.80xvs Biotechnology peers
Book Value per Share (MRQ)
0.4790USDUpdated Jul 19, 2026Total Assets
184.99MUSDvs all stocks (USD)
Total Current Assets
101.89MUSDFY2025 · Dec 31, 2025Total Liabilities
77.45MUSDFY2025 · Dec 31, 2025Total Non-current Assets
83.09MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
56.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.87MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
34.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
61.90MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.38MUSDFY2025 · Dec 31, 2025Inventory
281.00KUSDFY2025 · Dec 31, 2025Accounts Payable
3.08MUSDFY2025 · Dec 31, 2025Short-term Debt
6.24MUSDFY2025 · Dec 31, 2025Long-term Debt
56.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
366.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.02BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
107.54MUSDvs all stocks (USD)
Treasury Stock
5.19MUSDFY2025 · Dec 31, 202552-Week Low
1.00USDUpdated Jul 19, 202652-Week High
2.68USDUpdated Jul 19, 202652-Week Change
94.31%vs all stocks
Beta
1.05xvs all stocks
50-Day MA
2.14USDUpdated Jul 19, 2026200-Day MA
1.63USDUpdated Jul 19, 2026Avg 10-Day Volume
2.76MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.90MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.0700USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 99.5%, higher than 95% of its Biotechnology peers (median 78%)Significant
Gross margin: 0.99Industry median: 0.78Industry P95: 0.98Peers compared: 197
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 15.72Receivables vs revenue divergence: 3.96
High gross margins eroded by operating costsNotable
Gross Margin: 0.99Profit Margin: -0.37
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Changchun BCHT Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule